The first quarter of 2022 was one to forget for the biotech industry.
A public market downturn that began last year accelerated, sending the stock values of many biotech companies spiraling lower. The pace of drugmaker initial public offerings, which set a record in 2021, slowed to a trickle, making the path to Wall Street harder for emerging startups. Biotechs tightened their purse strings, leading to a string of restructurings.
Still, there were a few bright spots.The Food and Drug Administration approved a first-of-its-kind cancer immunotherapy, while a pioneering gene editing treatment continued to show promise and a major acquisition closed, calming concerns of greater regulatory scrutiny on buyout deals.
Several key FDA decisions lie ahead in the second quarter and each, if positive, may help the sector regain its momentum. Here are five to watch:
FDA advisory committee meetings are important moments for drugmakers as their outcomes can have a significant impact on a prospective medicine's approval chances. A two-day gathering in June is even more important for Bluebird, which could run out of money if the FDA doesn't approve two gene therapies a group of experts are set to review.
The gene therapies, known as beti-cel and eli-cel, would be just the third and fourth gene therapies for inherited diseases to reach market in the U.S. They would represent significant medical advances for patients with the blood disease beta thalassemia and the childhood brain disorder cerebral adrenoleukodystrophy.
Approvals also would lead the FDA to award the company with two priority review vouchers that can speed up drug reviews and be sold to other companies.
Bluebird has said those vouchers are critical to its financial future. In March, the company's top financial executive resigned amid a cash crunch that could leave the company insolvent within a year. Selling the vouchers could extend its runway and give Bluebird the chance to rebound.
However, Bluebird needs the blessing of the FDA and its advisers first, neither of which are a given. Both programs have been slowed in the past due to safety concernsand testing of eli-cel is on hold after a clinical trial participant developed a type of bone marrow cancer. The FDA extended its review of both drugs earlier this year.
The two-day advisory panel will take place on June 9 and June 10. The FDA will decide whether to approve beti-cel by Aug. 19 and eli-cel by Sept. 16.
Bristol Myers Squibb has been largely absent from major dealmaking since absorbing Celgene in a merger three years ago. However,the one time the pharma company did spring for a deal was in October 2020, when it paid $13 billion to buy MyoKardia and a heart drug known as mavacamten.
Bristol Myers was willing to pay that high price on optimism that mavacamten could become a top seller. On a conference call in February, CEO Giovanni Caforio pointed to the drug, which treats a typically inherited heart condition known as hypertrophic cardiomyopathy, as one of three emerging treatments in its pipeline with "at least $4 billion in revenue potential." Hitting those numbers will be key for Bristol Myers, as some of its most lucrative products will lose patent protection later this decade.
Still, commercial success is no guarantee. Many patients with hypertrophic cardiomyopathy don't have symptoms, and other medications and surgical options are available. Competition could be looming in the form of a similar drug from Cytokinetics that's in late-stage testing. On the February call, some analysts also questioned Bristol Myers' projections, which rely heavily on a sharp increase in diagnosis rates.
The FDA in November extended its review of mavacamten to evaluate a proposed post-approval patient monitoring plan, the details of which Bristol Myers hasn't shared. Its decision deadline is April 28.
The FDA is set to issue a verdict by June 29 on what could become the first new ALS drug to reach the U.S. market in five years.
ALS, better known to some as amyotrophic lateral sclerosis or Lou Gehrig's disease, is a progressive and fatal disorder hallmarked by the breakdown of nerve cells and the deterioration of essential functions like walking, eating and breathing. Patients with the disease typically live just two to five years after being diagnosed.To date, the FDA has cleared only two treatments specifically for ALS, each with limited effects on function and survival.
Amylyx Pharmaceuticals, a small drug company based in Cambridge, Massachusetts, believes it has another option in a pairing of chemicals named AMX0035. In a study of about 140 patients, Amylyx said those who received its medicine declined significantly slower compared to those on a placebo, as measured by a rating scale used to evaluate day-to-day functions in ALS patients. Amylyx also said that further analyses from an extension phase of the study found a benefit on survival.
The company, patient advocates and some doctors believe these outcomes offer enough evidence to approve AMX0035. The FDA has shown interest in the drug as well, allowing Amylyx to submit it while running another, larger study to confirm the results seen so far. However, the agency also has reservations about the way Amylyx designed its key study and the ways in which data were analyzed. Such concerns were on display during a meeting this week, in which neuroscience and drug development experts advised the FDA against approving AMX0035 in a narrow vote.
That vote puts the agency in a difficult position. ALS patients and advocacy groups have campaigned for the approval of more treatments, including Amylyx's, noting the limited options currently available as well as the devastating and fatal nature of their disease. The FDA has met with advocates and said it's listening to them, but with the crux of Amylyx's approval application in doubt, regulators could hold off green-lighting the company's drug until that larger study produces full results in 2024.
By late June, the FDA will decide whether to approve Bristol Myers' CAR-T cell therapy Breyanzi for earlier treatment of a common form of lymphoma.
To date, the complex cancer treatments have only been cleared for use after patients have run out of other options, limiting their reach and commercial potential. However, last year Bristol Myers and Gilead presented clinical trial data showing their respective CAR-T therapies Breyanzi and Yescarta outperformed standard "second-line" treatment, a combination of chemotherapy and stem cell transplant.
The results were a major proof point for CAR-T, which had reached market in the U.S. based on smaller studies without control arms. They were also validation for Bristol Myers and Gilead, both of which spent billions of dollars to acquire the products.
Gilead is likely to beat Bristol Myers to an approval, with an FDA decision expected imminently for Yescarta in second-line treatment. Yescarta has also been approved for longer, with an additional clearance for another lymphoma type.
However, approvals in second-line lymphoma could also draw renewed attention to the cost and manufacturing issues of CAR-T treatment. Bristol Myers priced Breyanzi at $410,000, while Yescarta has a list price of $373,000. Both companies require several weeks to produce the personalized treatments, a challenge that may grow more difficult if a broader group of patients are eligible.
Over the past year, the FDA office in charge of reviewing new cancer medicines has revisited its approach to accelerated approvals, most notably convening a meeting of outside experts last spring to review six previously granted OKs.
Agency officials have penned opinion pieces signaling tougher standards. FDA pressure has also led a number of companies to withdraw accelerated approval applications. Some companies have even pulled previously cleared drug indications after they were unable to confirm benefits observed in earlier testing.
The FDA's scrutiny appears to be turning next to a class of cancer medicines known as PI3K inhibitors, several of which are already on the market. In late April, the agency will again gather its panel of advisers to review whether randomized trial data is needed to appropriately support their use.
The group will also discuss an application by TG Therapeutics for accelerated approval of a combination drug regimen containing its marketed PI3K blocker Ukoniq. Previously, the FDA had announced an investigation into a possible increased risk of death with the medicine.
The agency has set a target decision date of June 25 for TG's treatment combination.
Already, the FDA's focus on PI3K inhibitors appears to have had an effect. In January, Gilead said it would withdraw two indications for its drug Zydelig after having difficulty enrolling patients in confirmatory studies. In addition,the agency told MEI Pharma and partner Kyowa Kirin this month that they would need to gather more data for their experimental PI3K inhibitor before seeking approval.
See the original post:
5 FDA decisions to watch in the second quarter - BioPharma Dive
- Mass. Law About Stem Cell Research - Massachusetts Trial ... [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Theres a New Anti-ALS Association Ice Bucket Challenge [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- Expert: Catholic objections wont leave ALS fundraiser all wet [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- Gene expression patterns in pancreatic circulating tumor cells revealed [Last Updated On: September 24th, 2014] [Originally Added On: September 24th, 2014]
- Inner Cell Mass - Embryonic Development & Stem Cells ... [Last Updated On: September 27th, 2014] [Originally Added On: September 27th, 2014]
- Mass production of placenta stem cells gets FDA approval ... [Last Updated On: September 27th, 2014] [Originally Added On: September 27th, 2014]
- Siamab Therapeutics Appoints Robert Mashal to Board of Directors [Last Updated On: October 9th, 2014] [Originally Added On: October 9th, 2014]
- Brain Tumor Stem Cell Lab - Massachusetts General Hospital ... [Last Updated On: October 9th, 2014] [Originally Added On: October 9th, 2014]
- 107.23 /$ (5 p.m.) [Last Updated On: October 15th, 2014] [Originally Added On: October 15th, 2014]
- Stem Cell Eye Treatment May Restore Vision [Last Updated On: October 16th, 2014] [Originally Added On: October 16th, 2014]
- Scientists Engineer Cancer-Killing Stem Cells [Last Updated On: October 26th, 2014] [Originally Added On: October 26th, 2014]
- Stem Cell Therapy, Stem Cell Biology at Mass General Hospital [Last Updated On: October 31st, 2014] [Originally Added On: October 31st, 2014]
- Harvard researchers genetically 'edit' human blood stem cells [Last Updated On: November 6th, 2014] [Originally Added On: November 6th, 2014]
- Human blood stem cells genetically 'edited' [Last Updated On: November 7th, 2014] [Originally Added On: November 7th, 2014]
- Critical Mass of Stem Cells Sets Off Embryonic Development ... [Last Updated On: November 12th, 2014] [Originally Added On: November 12th, 2014]
- Reprogramming cells, long term [Last Updated On: November 18th, 2014] [Originally Added On: November 18th, 2014]
- Pain and itch neurons grown in a dish [Last Updated On: November 25th, 2014] [Originally Added On: November 25th, 2014]
- Blood test could pick up risk of cancer five years in advance, say Harvard scientists [Last Updated On: November 28th, 2014] [Originally Added On: November 28th, 2014]
- The obesity pill that could replace exercise by turning 'bad' fat to 'good' [Last Updated On: December 9th, 2014] [Originally Added On: December 9th, 2014]
- Stem cells: The black box of reprogramming [Last Updated On: December 11th, 2014] [Originally Added On: December 11th, 2014]
- Canadian scientists crack stem cell reprogramming code [Last Updated On: December 11th, 2014] [Originally Added On: December 11th, 2014]
- Proteins drive cancer cells to change states [Last Updated On: December 16th, 2014] [Originally Added On: December 16th, 2014]
- Massachusetts (Stem Cell) - what-when-how [Last Updated On: February 3rd, 2015] [Originally Added On: February 3rd, 2015]
- New Organ Liver Prize Gathers Momentum [Last Updated On: February 4th, 2015] [Originally Added On: February 4th, 2015]
- MIT researchers develop glucose-responsive diabetes treatment [Last Updated On: February 11th, 2015] [Originally Added On: February 11th, 2015]
- Scientists develop novel technique for finding drugs to combat malaria [Last Updated On: February 11th, 2015] [Originally Added On: February 11th, 2015]
- Could we soon have man-made blood? [Last Updated On: March 10th, 2015] [Originally Added On: March 10th, 2015]
- Protein that repels immune cells protects transplanted pancreatic islets from rejection [Last Updated On: March 10th, 2015] [Originally Added On: March 10th, 2015]
- Researchers identify a vital protein that can determine head and brain development [Last Updated On: March 13th, 2015] [Originally Added On: March 13th, 2015]
- Biomedical engineer developing nanomaterial for healing broken bones [Last Updated On: March 18th, 2015] [Originally Added On: March 18th, 2015]
- Scientists engineer toxin-secreting stem cells to treat ... [Last Updated On: October 19th, 2015] [Originally Added On: October 19th, 2015]
- Cloning/Embryonic Stem Cells - Genome.gov [Last Updated On: October 19th, 2015] [Originally Added On: October 19th, 2015]
- Stem Cell Facts - University of Massachusetts Medical School [Last Updated On: July 27th, 2016] [Originally Added On: July 27th, 2016]
- Stem Cell FAQ - Massachusetts General Hospital, Boston, MA [Last Updated On: July 27th, 2016] [Originally Added On: July 27th, 2016]
- Stem-cell-based therapy promising for treatment of breast ... [Last Updated On: September 26th, 2016] [Originally Added On: September 26th, 2016]
- What Are Stem Cells? - Massachusetts General Hospital ... [Last Updated On: November 22nd, 2016] [Originally Added On: November 22nd, 2016]
- New England Cord Blood Bank - Cord Blood and Cord Tissue ... [Last Updated On: November 22nd, 2016] [Originally Added On: November 22nd, 2016]
- Stem cell controversy - Wikipedia [Last Updated On: December 1st, 2016] [Originally Added On: December 1st, 2016]
- From Stem Cells to Human Development - September 2016 ... [Last Updated On: December 4th, 2016] [Originally Added On: December 4th, 2016]
- X4 joins hands with Yale on rare disease program - FierceBiotech [Last Updated On: August 6th, 2017] [Originally Added On: August 6th, 2017]
- TGF-1: ALS Astrocytes' Secret Sauce? - ALS Research Forum [Last Updated On: August 6th, 2017] [Originally Added On: August 6th, 2017]
- CRISPR fixes disease gene in viable human embryos - Nature.com [Last Updated On: August 6th, 2017] [Originally Added On: August 6th, 2017]
- Current humanized mice not good models for studying stem cell transplants, say researchers - Scope (blog) [Last Updated On: August 27th, 2017] [Originally Added On: August 27th, 2017]
- Mouse Model of Human Immune System Inadequate for Stem Cell ... - Technology Networks [Last Updated On: August 27th, 2017] [Originally Added On: August 27th, 2017]
- ORGANOID - Science Magazine [Last Updated On: August 27th, 2017] [Originally Added On: August 27th, 2017]
- Asymmetrex Introduces New Contract Service For Producing ... - PR Web (press release) [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
- For Lowell native, stem cell match becomes a match as friends - Lowell Sun [Last Updated On: September 2nd, 2017] [Originally Added On: September 2nd, 2017]
- Lymphoma Patient's Brain Tumor Disappeared After She Received JCAR017, Study Reports - Lymphoma News Today [Last Updated On: September 2nd, 2017] [Originally Added On: September 2nd, 2017]
- Doubts raised about CRISPR gene-editing study in human embryos - Nature.com [Last Updated On: September 2nd, 2017] [Originally Added On: September 2nd, 2017]
- Alternate Methods for Preparing Pluripotent Stem Cells ... [Last Updated On: September 25th, 2017] [Originally Added On: September 25th, 2017]
- Cloning/Embryonic Stem Cells - National Human Genome ... [Last Updated On: July 5th, 2018] [Originally Added On: July 5th, 2018]
- Boston, MA, Stem Cell Transplant, Weston, Nantucket ... [Last Updated On: January 10th, 2019] [Originally Added On: January 10th, 2019]
- Chronic variable stress activates hematopoietic stem cells ... [Last Updated On: April 12th, 2019] [Originally Added On: April 12th, 2019]
- Massachusetts Stem Cells | Stem Cell TV [Last Updated On: September 10th, 2019] [Originally Added On: September 10th, 2019]
- Comparison of Merus N.V. (MRUS) and Sage Therapeutics Inc. (NASDAQ:SAGE) - MS Wkly [Last Updated On: October 23rd, 2019] [Originally Added On: October 23rd, 2019]
- Reviewing Cellectis S.A. (CLLS)'s and Magenta Therapeutics Inc. (NASDAQ:MGTA)'s results - MS Wkly [Last Updated On: October 23rd, 2019] [Originally Added On: October 23rd, 2019]
- New study reveals why breast cancer spreads to the brain - USC News [Last Updated On: October 23rd, 2019] [Originally Added On: October 23rd, 2019]
- Arkuda bags $44M to target progranulin and head off inherited dementia - FierceBiotech [Last Updated On: November 9th, 2019] [Originally Added On: November 9th, 2019]
- New Podcast Sponsored by Asymmetrex Increases Awareness to the Need for Stem Cell Dose in Stem Cell Treatments - PR Web [Last Updated On: November 9th, 2019] [Originally Added On: November 9th, 2019]
- Exercise found to block chronic inflammation in mice - Harvard Gazette [Last Updated On: November 9th, 2019] [Originally Added On: November 9th, 2019]
- Top Emerging Technologies of the Year - Technowize [Last Updated On: December 29th, 2019] [Originally Added On: December 29th, 2019]
- Firm adds a new wrinkle to anti-aging products - Williamson Daily News [Last Updated On: January 5th, 2020] [Originally Added On: January 5th, 2020]
- Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018 - BioSpace [Last Updated On: January 10th, 2020] [Originally Added On: January 10th, 2020]
- 10 Of The Biggest World Revelations In The 21st Century - World Atlas [Last Updated On: February 29th, 2020] [Originally Added On: February 29th, 2020]
- Infrared Laser Treatment of TBI, PTSD, and Depression: An Expert Perspective - Psychiatry Advisor [Last Updated On: April 3rd, 2020] [Originally Added On: April 3rd, 2020]
- Startup targets glioblastoma tumors with CAR-T therapy - FierceBiotech [Last Updated On: May 28th, 2020] [Originally Added On: May 28th, 2020]
- Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise [Last Updated On: July 2nd, 2020] [Originally Added On: July 2nd, 2020]
- Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans - Cancer Therapy Advisor [Last Updated On: September 5th, 2020] [Originally Added On: September 5th, 2020]
- Be Biopharma debuts with $52M to advance engineered B-cell therapies - FierceBiotech [Last Updated On: October 24th, 2020] [Originally Added On: October 24th, 2020]
- NurOwn May Be Given to Early ALS Patients in US Who Finished Phase... - ALS News Today [Last Updated On: December 20th, 2020] [Originally Added On: December 20th, 2020]
- Orchard Therapeutics Outlines Comprehensive Presence at 2021 WORLDSymposium - GlobeNewswire [Last Updated On: February 1st, 2021] [Originally Added On: February 1st, 2021]
- How Coronavirus Damages Lung Cells Within Mere Hours And What Drugs Could Halt COVID-19 Infection - SciTechDaily [Last Updated On: February 1st, 2021] [Originally Added On: February 1st, 2021]
- On systemic sources of early life stress, and empathetic responses - MIT News [Last Updated On: June 6th, 2021] [Originally Added On: June 6th, 2021]
- Asymmetrex Will Present a New Test for Therapeutic Stem Cell Potency at the ISSCR 2021 Annual Meeting - PRNewswire [Last Updated On: June 23rd, 2021] [Originally Added On: June 23rd, 2021]
- Infertility: Men account for at least half of cases. So why have women shouldered the blame? - The Irish Times [Last Updated On: June 23rd, 2021] [Originally Added On: June 23rd, 2021]
- cGVHD Paradigm Gains Systemic Options Beyond Steroids, But Real-World Data Are Required - OncLive [Last Updated On: October 28th, 2021] [Originally Added On: October 28th, 2021]
- Stem cells: Sources, types, and uses - Medical News Today [Last Updated On: December 24th, 2021] [Originally Added On: December 24th, 2021]
- Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL - www.oncnursingnews.com/ [Last Updated On: January 5th, 2022] [Originally Added On: January 5th, 2022]
- January 2022: 2021 Papers of the year - Environmental Factor Newsletter [Last Updated On: January 5th, 2022] [Originally Added On: January 5th, 2022]
- MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults... [Last Updated On: March 25th, 2022] [Originally Added On: March 25th, 2022]